首页> 外国专利> USING ANTI-CD20 TYPE II ANTIBODY, HAVING HIGH ANTIBODY-INDUCED CELL-DEPENDENT CYTOTOXICITY (ADCC), COMBINED WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICIN FOR TREATING NON-HODGKIN LYMPHOMAS

USING ANTI-CD20 TYPE II ANTIBODY, HAVING HIGH ANTIBODY-INDUCED CELL-DEPENDENT CYTOTOXICITY (ADCC), COMBINED WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICIN FOR TREATING NON-HODGKIN LYMPHOMAS

机译：使用抗CD20 II型抗体，具有高抗体诱导的细胞毒性（ADCC），并与环磷酰胺，长春新碱和阿霉素联用治疗非霍奇金淋巴瘤

页面导航

摘要
著录项
相似文献

摘要

FIELD: medicine.;SUBSTANCE: group of inventions discloses a combination of antibody to CD20 type II, which is formed by glycoengineering humanised antibody B-Ly1, where the humanised antibody B-Ly1 has a variable region of heavy chain (VH) SEQ ID No. 7 and light chain variable region (VL) SEQ ID No. 20, and chemotherapeutic agents selected from a group comprising cyclophosphamide, vincristine and doxorubicin, applicable for treating B-cell non-Hodgkin Lymphoma, as well as use of the named antibody for preparing a drug.;EFFECT: group of inventions is effective in treating of B-cell non-Hodgkin lymphoma.;5 cl, 4 dwg, 3 tbl, 4 ex

机译：领域：发明组公开了一种通过糖工程化人源化抗体B-Ly1形成的CD20 II型抗体的组合，其中人源化抗体B-Ly1具有重链可变区（VH）SEQ ID 7号和轻链可变区（VL）SEQ ID No. 20，以及选自环磷酰胺，长春新碱和阿霉素的化学治疗剂，适用于治疗B细胞非霍奇金淋巴瘤以及使用所述抗体效果：一组发明有效治疗B细胞非霍奇金淋巴瘤; 5 cl，4 dwg，3 tbl，4 ex

著录项

公开/公告号RU2589704C2

专利类型
公开/公告日2016-07-10

原文格式PDF
申请/专利权人 ROSHE GLIKART AG;
展开▼

申请/专利号RU20100143454
发明设计人 SHARL DYUMONTE (FR);TOMAS FRISS (DE);FRANK KHERTING (DE);KRISTIAN KLAJN (CH);PABLO UMANA (CH);
展开▼

申请日2009-03-23
分类号A61K39/395;
国家 RU
入库时间 2022-08-21 14:10:38

相似文献

专利
外文文献
中文文献